Editas Medicine (EDIT)

$38.28 0.00 (0.00%)

16:00 EDT EDIT Stock Quote Delayed 30 Minutes

4 Top Stock Trades for Thursday: LCID, DKNG, DLTR, EDIT

By Bret Kenwell, InvestorPlace Contributor Sep 29, 2021

Lucid Motors, DraftKings, Dollar Tree and Editas Medicine were our top stock trades for Thursday. Now, let's look at how the charts set up.

EDIT Stock Is Plunging 20%. Here’s the Gene-Editing News Dragging It Down.

7 Gene Editing Stocks Promising to Change our DNA

Forget About the Genomic Revolution, the Proteomic Revolution Is Coming

Volume:

Previous Close -

Market Cap 2.61B

PE Ratio -11.23

EPS -3.41

Volume (Avg. Vol.) 1

Day's Range 38.28 - 38.28

52-Week Range 27.12 - 99.95

Dividend & Yield N/A (N/A)

EDIT Stock Predictions, Articles, and Editas Medicine News

From InvestorPlace
From the Web

Forget About the Genomic Revolution, the Proteomic Revolution Is Coming

By Luke Lango, InvestorPlace Senior Investment Analyst Sep 3, 2021

Thanks to one small protein sequencing startup, we're entering a new era of proteomics via NGPS technologies that will enable massively parallel protein sequencing.

Gene Editing Stocks: The Trial News Lifting NTLA, CRSP and EDIT Stocks Today

By Chris MacDonald, InvestorPlace Contributor Aug 23, 2021

Today, gene editing stocks are getting a big boost after an intriguing data release by Editas for the company's new SLEEK technology.

Gene Editing Stocks: Why EDIT, NTLA, CRSP Stocks Are Climbing Today

By Chris MacDonald, InvestorPlace Contributor Aug 5, 2021

Today, investors in gene editing stocks are seeing a lot of green as earnings were announced along with business updates from key players.

Editas Stock Isn’t Worth Buying This Early Into Treatment Development

By Alex Sirois Jul 21, 2021

EDIT stock is part of a pioneering movement in CRISPR gene editing, but there's no way to know whether the company will succeed long term.

The Top 3 Gene Editing Stocks to Own for the Next Decade

By Ian Cooper Jul 12, 2021

Gene editing could revolutionize the way we treat diseases. Along the way, it could also create substantial opportunity for related stocks.

The Top 7 Gene-Editing Stocks to Buy for the Biggest Scientific Breakthrough of the Century

By Luke Lango, InvestorPlace Senior Investment Analyst Jul 1, 2021

Doudna's breakthrough in CRISPR has since ushered in a new era of genetic engineering, making these the best gene-editing stocks to buy.

Gene Editing Stocks: Why EDIT, CRSP, NTLA Stocks Continue to Soar

By Chris MacDonald, InvestorPlace Contributor Jun 30, 2021

Today, gene editing stocks are soaring amid increasingly bullish sentiment in this sector following strong results from Intellia.

Midday Market Update: 10 Biggest Stock Gainers Today

By William White, InvestorPlace Writer Jun 30, 2021

Good afternoon, investors! We're taking a look at how the market is doing halfway through the day with a midday market update.

What Will the Stock Market Do Today? 3 Big Stories to Watch.

By Sarah Smith, Editor, Today's Market Jun 28, 2021

So what will the stock market do today? All eyes are on gene-editing stocks like NTLA and on recovering crypto prices.

Gene Editing Stocks: The Big News Lifting EDIT, BNGO, CRSP and NTLA Stocks

By Robert Lakin, InvestorPlace Contributor Jun 28, 2021

Gene editing stocks are getting a boost on Monday morning after Intellia Therapeutics said it was successful using CRISPR gene-editing therapy directed inside the body to an internal organ.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

By William White, InvestorPlace Writer Jun 28, 2021

Good morning! Let's get ready for trading to start off strong this week with a look at the biggest pre-market stock movers for Monday!

7 Stocks to Buy for May

By Tezcan Gecgil, InvestorPlace Contributor Apr 27, 2021

Broader markets be at all-time highs, but there are still opportunities for the coming months. Here are seven stocks to buy this May.

What Did the Stock Market Do Today? 3 Big Stories to Catch Up On.

By Sarah Smith, Editor, Today's Market Apr 16, 2021

So what did the stock market do today? Dogecoin prices and other cryptocurrencies stole the show, and CRISPR stocks sold off.

CRISPR Stocks: The Big Analyst Call Destroying CRSP, NTLA, EDIT Stocks Today

By Vivian Medithi Apr 16, 2021

A "sell" rating is one thing, but a price target barely half of the Thursday close? It's no wonder Editas stock is crashing, and taking other gene-editing stocks with it.

Goldman Sachs Just Put Editas Stock on Sale — Buy the Dip

By Luke Lango, InvestorPlace Senior Investment Analyst Apr 16, 2021

Goldman says Editas' clinical data may underwhelm. We don't agree. So this is the time to buy the dip in EDIT stock.

Investing in CRISPR Stocks: Ultimate Genetic Editing Guide

By Luke Lango, InvestorPlace Senior Investment Analyst Apr 15, 2021

The biotech space is on the verge of hypergrowth, thanks to a scientific breakthrough in genetic editing. This is your ultimate guide to understanding and profiting from CRISPR stocks.

Gene Editing Stocks: What BLUE, NTLA, BEAM, CRSP and EDIT Are Doing Today

By William White, InvestorPlace Writer Mar 10, 2021

Gene editing stocks are on the move Wednesday with investors taking extra interest in biotech companies on news from two major players.

A Play on the Biggest Scientific Breakthrough of the Century

By Luke Lango, InvestorPlace Senior Investment Analyst Jan 22, 2021

There are only a handful of large, well-established gene editors with robust and mature therapy pipelines in the world today. Of those, one that stands out is a $4.8 billion biotechnology company by the name of Editas Medicine (NASDAQ:EDIT).